卡羅林斯卡研究所的研究表明，CELLINK的I-DOT液體處理系統可以進行遺傳癌症診斷研究 返回
卡羅林斯卡研究所（Karolinska Institute）的最新研究表明，I-DOT具有促進癌症診斷基因研究的能力。瑞典的卡羅林斯卡研究所（Karolinska Institute）處於世界癌症研究的最前沿。
卡羅林斯卡研究所和生命科學實驗室已經開發出一種稱為CUTseq的新方法，該方法可經濟高效地鑑定高度異質性腫瘤，這些腫瘤通常具有很強的侵襲性，需要積極治療。該方法適用於從多個活檢組織甚至從薄薄的組織切片的極小部分（即病理學家通常在顯微鏡下診斷癌症的樣本）中提取的DNA。這項研究最近發表在科學雜誌《自然通訊》上。
在癌症研究之外，CUTseq還用作鑑定細胞系和監測通量的方法。傳統上，液體處理對交叉污染敏感。這項研究表明，I-DOT在CUTseq工作流程中不易受到交叉污染的影響，這與降低成本，更快的結果和增強的重現性相對應。使用I-DOT，研究人員能夠完成整個工作流程，從提取提取的RNA和DNA一直到文庫純化一直到大約8小時。
I-DOT由德國公司Dispendix GmbH開發，該公司於2018年11月被CELLINK收購，以擴大其在製藥行業市場的佔有率。這項研究的結果為I-DOT在腫瘤學研究中的應用奠定了基礎，並可以支持細胞系開發中的其他應用。
Karolinska Institute study shows CELLINK’s I-DOT liquid-handling system can enable genetic cancer diagnostic research
New research from the Karolinska Institute has demonstrated the I-DOT’s capability to facilitate genetic research in cancer diagnostics. The Karolinska Institute in Sweden is at the forefront of cancer research in the world.
Karolinska Institute and Science for Life Laboratory have developed a new method called CUTseq, a cost-effective way to identify highly heterogenous tumors that are often very aggressive and require aggressive treatments. The method works with DNA extracted from multiple biopsies and even from very small portions of thin tissue sections, i.e., the type of sample that pathologists commonly rely on to make a diagnosis of cancer under the microscope. The research has been recently published in the scientific journal Nature Communications.
Outside of cancer research, CUTseq is also used as a method of authenticating cell lines and monitoring throughput. Traditionally, liquid handling is sensitive to cross contamination. This study showed I-DOT was not susceptible to cross contamination during the CUTseq workflow, which corresponds to reduced costs, faster results and enhanced reproducibility. Using the I-DOT, the researchers were able to complete the entire workflow from taking the extracted RNA and DNA all the way through library purification to results in ~8 hours.
I-DOT is developed by Germany-based company Dispendix GmbH, a company CELLINK acquired in November 2018 to increase its presence in the pharmaceutical industry market. The results of this study lay the groundwork for I-DOT’s use in oncological research and can support additional applications in cell line development.
